Relatively favorable outcomes of post-transplant pulmonary function in patients with chronic myeloid leukemia receiving non-myeloablative allogeneic hematopoietic stem cell transplantation

M. Y. Lee, Tzeon Jye Chiou, M. H. Yang, L. Y. Bai, L. T. Hsiao, T. C. Chao, S. L. Tung, W. S. Wang, C. C. Yen, J. H. Liu, P. M. Chen

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Pulmonary function tests were performed in 20 patients with chronic myeloid leukemia before and after human leukocyte antigen-matched allogeneic sibling hematopoietic stem cell transplantation (HSCT) to identify any conditioning treatment effects on post-transplant function from January 1995 to December 2002. Of 20 patients, eight received non-myeloablative conditioning treatment and 12 received conventional myeloablative conditioning treatment. Pulmonary function tests including forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and diffusion capacity for carbon monoxide (DLCO) were performed pretransplant, 6 and 12 months post-transplant. Possible pre-HSCT and post-HSCT risk factors were evaluated for association with pulmonary function. The results showed that myeloablative conditioning treatment had greater negative impact on FEV1, FVC, and DLCO than non-myeloablative conditioning therapy. We conclude that non-myeloablative allogeneic HSCT may apply a better transplant choice in patients who need special concern with post-transplant pulmonary function changes.

Original languageEnglish
Pages (from-to)152-157
Number of pages6
JournalEuropean Journal of Haematology
Volume74
Issue number2
DOIs
Publication statusPublished - Feb 2005
Externally publishedYes

Keywords

  • Chronic myeloid leukemia
  • Graft-vs.-host disease
  • Hematopoietic stem cell transplantation
  • Non-myeloablative stem cell transplantation
  • Pulmonary function

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Relatively favorable outcomes of post-transplant pulmonary function in patients with chronic myeloid leukemia receiving non-myeloablative allogeneic hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

Cite this